Literature DB >> 31550151

The Exploration of Chirality for Improved Druggability within the Human Kinome.

Debasmita Saha1, Anupreet Kharbanda1, Wei Yan1, Naga Rajiv Lakkaniga1, Brendan Frett1, Hong-Yu Li1.   

Abstract

Chirality is important in drug discovery because stereoselective drugs can ameliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles. The human kinome, a major druggable enzyme class has been exploited to treat a wide range of diseases. However, many kinase inhibitors are planar and overlap in chemical space, which leads to selectivity and toxicity issues. By exploring chirality within the kinome, a new iteration of kinase inhibitors is being developed to better utilize the three-dimensional nature of the kinase active site. Exploration into novel chemical space, in turn, will also improve drug solubility and pharmacokinetic profiles. This perspective explores the role of chirality to improve kinome druggability and will serve as a resource for pioneering kinase inhibitor development to address current therapeutic needs.

Entities:  

Year:  2019        PMID: 31550151     DOI: 10.1021/acs.jmedchem.9b00640

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Enantiomeric Resolution and Absolute Configuration of a Chiral δ-Lactam, Useful Intermediate for the Synthesis of Bioactive Compounds.

Authors:  Roberta Listro; Giacomo Rossino; Serena Della Volpe; Rita Stabile; Massimo Boiocchi; Lorenzo Malavasi; Daniela Rossi; Simona Collina
Journal:  Molecules       Date:  2020-12-19       Impact factor: 4.411

2.  Biological Properties of New Chiral 2-Methyl-5,6,7,8-tetrahydroquinolin-8-amine-based Compounds.

Authors:  Giorgio Facchetti; Michael S Christodoulou; Lina Barragán Mendoza; Federico Cusinato; Lisa Dalla Via; Isabella Rimoldi
Journal:  Molecules       Date:  2020-11-27       Impact factor: 4.411

Review 3.  Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019.

Authors:  Xuetong Chu; Yizhi Bu; Xiaoping Yang
Journal:  Front Oncol       Date:  2021-12-17       Impact factor: 6.244

4.  Design, Synthesis, and Evaluation of New Mesenchymal-Epithelial Transition Factor (c-Met) Kinase Inhibitors with Dual Chiral Centers.

Authors:  Han Yao; Yuanyuan Ren; Jun Yan; Jiadai Liu; Jinhui Hu; Ming Yan; Xingshu Li
Journal:  Molecules       Date:  2022-08-23       Impact factor: 4.927

5.  Efficient and Divergent Enantioselective Syntheses of DHPVs and Anti-Inflammatory Effect on IEC-6 Cells.

Authors:  Hyun Su Kim; Sungkyun Chung; Moon-Young Song; Changjin Lim; Hyeyoung Shin; Joonseong Hur; Hyuk Kwon; Young-Ger Suh; Eun-Hee Kim; Dongyun Shin; Seok-Ho Kim
Journal:  Molecules       Date:  2020-05-08       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.